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Concomitant inhibition of FLT3 and MCL-1 in
FLT3 mutated Acute Myeloid Leukemia
Paul Fajardo Panis, M.S
Advisory Professor: Marina Konopleva, MD, Ph.D

Abstract
The MCL-1 inhibitor S63845 synergizes with the FLT3 inhibitor midostaurin for potent
anti-leukemic effect in preclinical human models of FLT3-ITD mutated acute myeloid leukemia
(AML). Acute Myeloid leukemia (AML) is a neoplastic blood disorder defined by a
characteristically rapid growth rate and altered behavior of myeloid cells in the bone marrow. The
FLT3 receptor is responsible for the upstream regulation of many key processes in hematopoietic
cells. FLT3 internal tandem duplication (ITD) mutations are common in leukemia and have been
observed in up to a third of newly diagnosed AML patients. FLT3-ITD have been implicated as a
driver mutation partly responsible for disease progression and associated with increased risk of
relapse and lower probability of survival. This leads to the constitutive activation of the FLT3-ITD
receptor and consequently the activation of downstream constituents central to regulating cellular
functions. The ultimate outcome of FLT3-ITD mutations in AML is the loss of homeostasis in
hematopoietic cells and progression of the leukemic disease state. Inhibitors of the FLT3 receptor
inhibit activation and subsequent downstream phosphorylation in pathway which promote AML
survival and progression. The FLT3 inhibitor midostaurin acts upon possessing the FLT3 receptor
and displays therapeutic efficacy against the constituently active FLT3-ITD receptor. The addition
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of midostaurin is a significant advance in leukemic armamentarium, but there are still challenges
for the treatment of FLT3-mutated AML through the development of therapy resistance.
Among mechanisms of resistance to TKI that arise from non-FLT3 dependent pathways,
most notable are the resistance mechanisms relating to the cell's systems which govern the
apoptotic process. This has led to interest in the pro-survival BCL-2 family member MCL-1 due
to the observation across cancers of therapy resistance and relapse associated with its
amplification. Of relevance to our project is the selective MCL-1 inhibitor S63845. In preclinical
studies, S63845 was found to exhibit dose-dependent anti-tumor activity in-vitro and was found
to be well tolerated by mice in the in-vivo studies.
Here we studied the pre-clinical efficacy of S63845 and midostaurin in AML cell lines
expressing FLT3-WT or mutant FLT3-ITD receptor. S63845 in combination with midostaurin
synergistically promoted anti-leukemic effect in-vitro. Midostaurin lead to the reduction of MCL1 and sensitized cells to MCL-1 inhibition. Mechanistically, midostaurin lead to changes in MCL1 phosphorylation and promotion of its proteasomal degradation. In addition, because resistance
to the BCL-2 inhibitor venetoclax is characterized diminished by upregulation of MCL-1 we also
studied the impact of the combination of venetoclax resistant FLT3-ITD AML cells. Overall, our
results indicate sensitivity towards the combination of midostaurin and S63845 in venetoclax
resistant AML cells. This supports the use of the combination of S63845 and midostaurin as a
second line treatment in the event of treatment failure or relapse post-venetoclax therapy in FLT3ITD AML.
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Figure 6: MCL-1 anti-apoptotic action and inhibition by S63845 in AML (Pg. 11)



Figure 7: The efficacy of midostaurin and S63845 in AML cells. FLT3-ITD positive and
FLT3-WT AML cells were treated with increasing doses of S63845 and midostaurin given alone
or at dose combinations. After a 24 hour period the inhibition of cell viability was quantified by
CellTiter-Glo (CTG) assay and Bliss Independence Analysis performed to determine the nature of
drugs’ interactions. BLISS index values >0 indicate synergy while values <0 indicate antagonism.
Results displayed are the average of three independent experiments. The top matrix represents %
inhibition of cell viability. Directly below each matrix are respective Bliss index scores and total
synergy sum. A) FLT3-ITD positive AML results for % inhibition and Bliss analysis for
combination treatment in FLT3-ITD cells B) FLT3-WT AML results for % inhibition and Bliss
analysis for combination treatment in FLT3-ITD cells. (Pg. 18)



Figure 8: The inhibition of mutated FLT3 synergizes with targeting of MCL-1 in human
and murine AML leukemia cell lines. AML cell lines treated with increasing doses of S63845
and A) midostaurin or B) gilteritinib given alone or at dose combinations. After a 24 hour period
the inhibition of cell viability was quantified by CellTiter-Glo (CTG) assay and Bliss
Independence Analysis performed, where Bliss index values >0 indicates synergy for dose
combination, while values <0 indicate antagonism. Results displayed are the average of three
replicate experiments. The top matrix represents % inhibition of cell viability. Directly below
each matrix are respective Bliss index scores and total synergy sum. A) Isogeneic murine Ba/F3
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cell lines carrying FLT3-WT, FLT3-ITD, FLT3-ITD-D835Y, or FLT3-ITD-F691L mutations
treated with midostaurin and S63845. Results for % inhibition and Bliss analysis confirms
sensitivity to therapy and synergistic response towards combination in FLT3-ITD mutants
compared to FLT3-WT cells. B) Human FLT3-ITD AML cells treated with S63845 and another
FLT3 inhibitor, gilteritinib. The results for % of viability inhibition and Bliss index analysis
confirm that dual targeting of mutated FLT3 and MCL-1 is effective in AML cells. (Pg. 20)


Figure 9: Midostaurin and S63845 combination effectively induces apoptosis in FLT3mutated AML cells. Annexin V-FITC/DAPI staining and analysis by flow cytometry for specific
apoptosis in FLT3-ITD AML. Cells were treated with increasing doses of S63845 and
midostaurin given alone or at dose combinations for 24 hours. A) Representative histograms
showing effects of single treatment S63845 (top left to top right), single treatment midostuarin
(top left to bottom left) and combination are displayed. S63845 and midostaurin are observed to
promote apoptosis in a dose dependent manner as increased the doses of respective drug
increasingly shifts the population of cells from the alive state (bottom left quadrant) to the early
apoptotic state (bottom right quadrant). B) Results displayed are the average of three replicate
experiments. Respective values for specific apoptosis and Bliss Independence Analysis for each
cell line. The top matrix displays specific apoptosis while directly below are Bliss analysis scores
and total synergy sum, where values >0 indicates synergy for dose combination. Overall results
indicate synergistic response towards combination in FLT3-ITD AML cell lines. (Pg. 22)



Figure 10: Gilteritinib and S63845 combination effectively induces apoptosis in FLT3mutated AML cells. Annexin V-FITC/DAPI staining and analysis by flow cytometry for specific
apoptosis in FLT3-ITD AML. Cells were treated with increasing doses of S63845 and gilteritinib
given alone or at dose combinations for 24 hours. A) Representative histograms showing effects
of single treatment S63845 (top left to top right), single treatment gilteritinib (top left to bottom
left) and combination are displayed. S63845 and gilteritinib are observed to promote apoptosis in
a dose dependent manner as increased the doses of respective drug increasingly shifts the
ix

population of cells from the alive state (bottom left quadrant) to the early apoptotic state (bottom
right quadrant). B) Results displayed are the average of three replicate experiments. Respective
values for specific apoptosis and Bliss Independence Analysis for each cell line. The top matrix
displays specific apoptosis while directly below are Bliss analysis score and total synergy sum,
where values >0 indicates synergy for dose combination. Outcome is concordant with results
presented in Figure 3 and supports strategy of dual FLT3 and MCL-1 inhibition to promote
apoptosis in FLT3-ITD AML. (Pg. 24)


Figure 11: Western Blot analysis of apoptotic markers: cleaved PARP and caspase-3 in
AML cells following dual FLT3 and MCL-1 inhibition. AML cells were treated with DMSO,
10 nM S63845, 100 nM midostaurin or combination for 6 hours and analyzed by Western Blot.
Promotion of apoptosis is observed to be superior in combination condition over single agent
conditions. Cleaved PARP and cleaved caspace-3 protein for combination is greater than the
amount of respective proteins observed for either S63845 or midostaurin alone. B) MV4-11 cells
were treated with DMSO, 10 nM gilteritinib, 10 nM S63845, or combination for 6 hours then
analyzed by Western Blot for cleavage of PARP and caspase-3. Results are concordant with those
presented in Figure 5A and supports the link between dual FLT3 and MCL-1 inhibition in FLT3ITD AML and promotion of apoptosis. (Pg. 26)



Figure 12: The effect of midostaurin on the level of MCL-1 protein in FLT3-ITD AML and
FLT3-WT AML. FLT3-ITD and FLT3-WT AML cells were treated with DMSO or 100 nM
midostaurin for 6 hours. Samples were then analyzed by Western Blot for examination of MCL-1
protein levels. FLT3-ITD cells exhibited profound reduction in MCL-1 level upon midostaurin
treatment while MCL-1 protein levels remained mostly unaffected in FLT3-WT cells. Results
lends towards indication that MCL-1 expression is linked to abnormal FLT3-ITD activity and
inhibition of FLT3-ITD leads to down regulation of MCL-1 in FLT3-ITD AML. (Pg. 27)



Figure 13: Impact of FLT3 and MCL-1 inhibition on the components of FLT3 signaling
pathway. A) MV4-11 and MOLM14 cells were treated with DMSO, 10 nM S63845, 100 nM
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midostaurin or combination for 6 hours and analyzed by Western Blot. Midostaurin treatment
alone led to downregulation of phosphorylated FLT3 and its downstream effectors:
phosphorylated STAT5, AKT, and MAPK. S63845 treatment alone did not have observable
impact on FLT3 signaling pathway. Drug combination caused a reduction of phosphorylation of
the FLT3 signaling pathway mirroring effect of midostaurin treatment. B) MV4-11 cells were
treated with DMSO, 10 nM gilteritinib, 10 nM S63845, or combination. Results support the
outcome observed with midostaurin treatment and are in agreement with general scheme of
inhibition of FLT3 signaling pathway. C) Effect of midostuarin and S63845 combination on the
level of MCL-1 and pro-apoptotic BIM. Midostaurin-induced reduction in MCL-1 was
accompanied by the shift in electrophoretic mobility of BIM. Single agent S63845 led to an
increase of MCL-1 stability with no changes to BIM. Combination treatment mirrored the
outcome observed for midostaurin alone. D) The results of combination of gilteritinib with
S63845 follow the same trend as for midostaurin and suggest that the decrease in MCL-1 and
change in BIM electrophoretic mobility are due to FLT3 inhibition rather than result from offtarget effects of midostaurin or gilteritinib. (Pg. 29)


Figure 14: Time-dependent effect of midostuarin on FLT3-mediated signaling pathways in
MV4-11 cells. Cells were incubated with 100 nM midostaurin at hourly times points of 1, 2, 4,
and 6. A) Within the first hour of treatment with midostaurin a down regulation of
phosphorylation was observed for FLT3, AKT, Gsk3, and MAPK. Reduction of MCL-1
phosphorylated at Ser159 and Thr163 was observed after 2 hours with a subsequent gradual
decrease of total MCL-1 levels. B) The levels of BCL-XL and BCL-2 remain unaffected upon
treatment with midostaurin. The BIM protein exhibits a mobility shift within the first hour of
midostaurin treatment which suggests immediate dephosphorylation of BIM. (Pg. 31)



Figure 15: Time-dependent effect of midostuarin on FLT3-mediated signaling pathways in
MOLM13 and MOLM14 cells. Cells were incubated with 100 nM midostaurin at hourly times
points of 1, 2, 4, and 6. A) Within the first hour of treatment with midostaurin a down regulation
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of phosphorylation is observed for FLT3, AKT, Gsk3, and MAPK. A slight amount of
phosphorylation is observed around hour 6 for MAPK. B) While MCL-1 decreases with
prolonged exposure to midostaurin, the levels of BCL-XL and BCL-2 do not show any changes
upon treatment. The BIM protein exhibits a mobility shift within the first hour of midostaurin
treatment which indicates immediate dephosphorylation of BIM. Overall results are in support of
observations seen with MV4-11 kinetics. (Pg. 33)


Figure 16: Proteasomal degradation of MCL-1 supported by caspase-mediated degradation
is responsible for a decrease of MCL-1 in response to midostaurin. A) For evaluation of
proteasomal contribution to MCL-1 downregulation, FLT3-ITD AML cells were pretreated for 1
hour with 0.5 M or 1 M of proteasome inhibitor MG-132 and co-incubated with DMSO or 100
nM midostaurin for next 6 hours. While midostaurin alone decreased Mcl-1, MG-132 alone
increased MCL-1 above baseline, indicating the occurrence of endogenous MCL-1 proteasomal
degradation. For combination conditions, MCL-1 downregulation by midostaurin is recused by
0.5 M MG-132 and this rescue is increased at 1.0 M MG-132. Noxa level was observed to
follow the same trend of expression as MCL-1 upon each treatment condition. B) For evaluation
of caspase cleavage contribution to MCL-1 downregulation, FLT3-ITD AML cells were
preincubated with pan-caspase inhibitor Z-VAD-FMK for 1 hour and co-incubated with DMSO
or 100 nM midostaurin for next 6 hours. midostaurin treatment led to reduction of MCL-1 while
Z-VAD-FMK alone increased MCL-1 level, indicating the occurrence of endogenous caspasemediated MCL-1 cleavage. Pre-treatment with Z-VAD-FMK only slightly prevented degradation
of MCL-1 induced by midostaurin indicating a minor involvement of caspase cleavage as
facilitator of midostaurin-induced MCL-1 degradation. Noxa protein levels followed the same
expression trend MCL-1 for each treatment condition. (Pg. 35)



Figure 17: Impact of dual FLT3 and MCL-1 inhibition on MCL-1 level in parental
MOLM13 and venetoclax resistant MOLM13 cells. AML cells were treated with DMSO, 10
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nM S63845, 100 nM midostaurin or combination for 6 hours then analyzed by Western Blot.
Greater basal MCL-1 protein level is observed in venetoclax resistant cells compared to their
parental counterparts suggesting higher dependency on MCL-1 for the survival. Parallel trends of
response was observed between cell lines for midostaurin, S63845 and combination conditions.
Treatment conditions did not induce any changes in BCL-2 levels in either cell line. While BIM
exhibited protein mobility shifts for conditions treated with midostaurin, overall response trends
concordant between the two cell lines. (Pg. 37)


Figure 18: Dual targeting of MCL-1 and mutated FLT3-ITD is effective in venetoclax
resistant AML cells. MOLM13 parental and MOLM13 venetoclax resistant cells treated with
increasing doses of S63845 and midostaurin given alone or at dose combinations. After a 24 hour
period the inhibition of cell viability was quantified by CellTiter-Glo (CTG) viability assay and
Bliss Independence Analysis performed, where values >0 indicates synergy and <0 antagonism
for dose combination. The top matrix represents % inhibition of viability. Directly below each
matrix are respective Bliss analysis scores and total synergy sum. Comparison of Bliss Index
sums indicates superior synergistic effect of combination in venetoclax resistant MOLM13 cells
over parental MOLM13 cells. (Pg. 38)



Figure 19: Evaluation of apoptosis in parental and venetoclax resistant MOLM13 cells. A)
Annexin V-FITC/DAPI staining and analysis by flow cytometry for specific apoptosis was
performed in MOLM13 parental and venetoclax resistant cells treated with increasing doses of
S63845 and midostaurin given alone or at dose combinations for 24 hours. Representative
histograms showing effects of single treatment S63845 (top left to top right), single treatment
midostuarin (top left to bottom left) and combination are displayed. S63845 and midostaurin are
observed to promote apoptosis in a dose dependent manner as increased the doses of respective
drug increasingly shifts the population of cells from the alive state (bottom left quadrant) to the
early apoptotic state (bottom right quadrant). A superior response to combination treatment is
observed for venetoclax resistant MOLM13 over parental MOLM13 cells. B) Western blot
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analysis of apoptotic PARP and caspase-3 cleavage in MOLM13 parental and venetoclax
resistant cells treated with DMSO, 10 nM S63845, 100 nM midostaurin or combination for 6
hours. Greater cleavage in PARP and caspase-3 upon single agent S63845 and combination
treatment was observed in venetoclax resistant MOLM13 cells over parental MOLM13 cells.
(Pg. 39)


Figure 20: Effect of phosphorylation on BIM (Pg. 43)



Figure 21: Schema of phosphorylation site and MCL-1 fate (Pg. 46)
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Introduction
Hematopoiesis and Leukemia
Hematopoiesis is the process in which the principal components of blood are
formed. Central to blood production are the pluripotent hematopoietic stem cells (HSC)
from which all hematopoietic cells are derived from. These immortal HSCs are necessary
for the replenishment of intermediately differentiated yet shorter-lived precursor cells.
Precursor cells go on to form distinct branches of maturation whereupon each branch
undergoes further differentiation. The terminal results of each differentiation path are fully
matured myeloid cells such as erythrocytes, thrombocytes, and leukocytes [1,2,105]. When
properly functioning, this process ensures the hematological demands of the healthy human
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body are met. Indeed, life would not be sustainable if not for the delicate system regulation
which maintains balance during hematopoiesis.
Hematologic diseases occur when balance within the hematopoiesis is disrupted,
and homeostasis is unable to be reestablished. Potential causes for disease include
environmental causes, somatic level genetic defects, and/or dysregulation of the various
systems maintaining the human body. Leukemia is a hematologic disease which is
composed of various families of hematologic cancers [3,106]. Common amongst leukemia
is transformation of cells towards the malignant state through the acquisition of
chromosomal rearrangements and/or multiple gene mutations. These changes confer
proliferative and survival advantages to leukemia cells which overtime can lead to systemic
harm and even death for the human body.

2

Acute Myeloid leukemia (AML) is a subcategory of leukemia defined by a
characteristically rapid growth rate and altered behavior of myeloid cells in the bone
marrow [3,4]. Left untreated, the proliferation and overabundance of leukemic cells can
lead to the secondary effects on the non-leukemic hematologic cells and exert strain on the
overall body. This ultimately culminates in a reduction of functional myeloid cells, the loss
of quality of life and increased susceptibility to opportunistic diseases.
The detection and diagnosis of AML typically involves physical examination by a
Physician and laboratory evaluation of a patient's blood and bone marrow for histologic,
cytogenetic, and molecular analysis [4]. Clinical and laboratory metrics of evaluation allow
categorization of a patient's disease into specific subfamilies of AML based on genetic or
chromosomal abnormalities [5]. This knowledge has significant clinical implications and
serves to guide the decision on which treatment plan is best for achieving remission. As of
2022, NIH SEER data indicates the AML demographic is expected to have a 5-Year
Relative Survival of 29.5% [6]. This limited life expectancy highlights the need to improve
clinical outcomes for the treatment of AML.
To this end, the FLT3-ITD mutated AML is a focus of therapeutic research for
manifold reasons. First, mutations in FLT3 are one of the most common mutations in
leukemia and have been observed in up to a third of newly diagnosed AML patients [7].
Second, FLT3-ITD have been implicated as a driver mutation partly responsible for disease
progression [8,9]. Lastly, FLT3 mutations have been associated with increased risk of
relapse and lower probability of survival when treated with conventional regimens [10-12].
Ultimately realization of clinical improvements will rely on rational utilization and
expansion of knowledge pertaining to the molecular underpinnings of FLT3-ITD AML.
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FLT3-ITD AML
The Fms Related Receptor Tyrosine Kinase 3 (FLT3) receptor is responsible for
the upstream regulation of many key processes in hematopoietic cells. The receptor belongs
to the Receptor Tyrosine Kinase (RTK) subclass III family and possess notable features
such as an immunoglobulin-like extracellular domains, a transmembrane domain, a
juxtamembrane domain ( JM) and an intracellular tyrosine kinase domain [13, 107]. The
FLT3 receptor is canonically activated by the FL ligand whereupon structural
reconfigurations are induced. This allows the structure to open up to permit access to ATP
binding domains essential for kinase function [14]. Subsequently the FLT3 receptor
becomes able to phosphorylate downstream proteins essential to development,
proliferation, and survival for hematopoietic cells. Altogether, the FLT3 receptor is an
important part of the hematopoiesis process, and its proper regulation is crucial for

maintaining healthy function in hematopoietic cells.
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In the context of AML, FLT3-ITD refers to the occurrence of internal tandem
duplication (ITD) mutations in the FLT3 receptor of hematopoietic cells. The FLT3-ITD
receptor is characterized by structural changes in the JM region which allow for ligandindependent dimerization and the circumvention of prior regulation by the FL ligand [14].
This leads to the constitutive activation of the FLT3-ITD receptor and consequently the
activation of downstream constituents central to regulating cellular functions. The ultimate
outcome of FLT3-ITD mutations in AML is the loss of homeostasis in hematopoietic cells
and progression of the leukemic disease state.
Since 1972 the historical treatment for AML has been the "7+3" chemotherapy
regimen. Consisting of scheduled doses of cytarabine and anthracycline, the result of
treatment is indiscriminate cytotoxic insult to both the patient's cancer and their healthy
cells to induce remission [15]. After a lull in new approvals for the treatment of AML, the
past decades of research and development have come to fruition for the treatment of FLT3ITD AML. Inhibitors for the FLT3 receptor are currently being investigated in clinics with
a number having successfully moved onto FDA approval.
FLT3 inhibitors are categorized as type I or type II inhibitors depending on the
location it binds to the FLT3 receptor. Currently Type I inhibitors are of interest in the
treatment of FLT3-ITD AML due to their superior inhibitory action against FLT3-ITD
receptors when compared to Type II inhibitors [16, 108]. Unlike Type II inhibitors, Type I
inhibitors can bind both the structurally active and inactive states of the FLT3 receptors.
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A prime example of a targeted therapeutic for AML would be the Type 1 FLT3
inhibitor midostaurin. In contrast to traditionally used chemotherapies which
systematically affect all cells, midostaurin therapeutically acts in a biased manner primarily
towards cells possessing the FLT3 receptor and displays therapeutic efficacy against the
constituently active FLT3-ITD receptor. Furthermore, this anti-leukemic effect was noted
to be further enhanced when combined with standard AML chemotherapy, which led to its
2017 FDA approval for administration as part of a therapeutic combination [17]. In sum,
the investigation of targeted therapies and the approval of midostaurin represent essential
steps forward in the treatment of AML.
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Midostaurin background
Midostaurin was discovered through an apoptotic compound screen in FLT3-ITD
positive Ba/F3 cells [18]. Additional studies of evaluating the efficacy and potency of
midostaurin found that cells expressing FLT3-WT and various FLT3-TKDs demonstrated
response in a similar manner to the FLT3-inhibitory activity in treated FLT3-ITD positive
cells. It was also found that despite response to midostaurin amongst FLT3-WT and FLT3
mutants, there was tenfold lower inhibition of FLT3-WT [19]. This made midostaurin a
favorable candidate for investigation in the clinical space for its overall inhibitory action
against FLT3 and increased potency against FLT3 mutated forms of AML.
The initial clinical stage investigations of midostaurin proved fruitful with
Relapsed/Refractory AML patients by achieving blast reductions in 71% of patients with
FLT3-mutated AML and reductions of 42% in patients with FLT3-WT AML [20]. This
led to the investigation of midostaurin in combination with standard 7 + 3 chemotherapy
in the RATIFY clinical trial. Enrolled subjects with FLT3 mutations were assigned to either
placebo or midostaurin treatment groups once standard chemotherapy regimen was
administered. The result of the study was an observed 22% lower risk of death in the
midostaurin plus chemotherapy group compared to the placebo plus chemotherapy [21,22].
The results of the RATIFY study ultimately led to the FDA approval of midostaurin in
combination with standard cytarabine and daunorubicin induction in April 2017 for the
treatment of adult patients with newly diagnosed FLT3-mutated AML [23-25]
The addition of midostaurin is a significant advance in leukemic armamentarium,
but there are still challenges for the treatment of FLT3-mutated AML. In a study exploring
the mechanism governing resistance in FLT3-ITD positive AML, it was found that at the
time of resistance or progression approximately half of patients became FLT3-ITD
7

negative while acquiring signal pathway mutations [24]. Despite the efficacy of the
midostaurin plus 7+3 combination in treated FLT3 mutated AML, only 59% were able to
achieve complete remission by the study protocol’s specifications and subsequently
roughly half of the patients which achieved CR succumbed to relapse. Most relevant to
note was that the other half of patients exhibited FLT3-ITD persistence only 11% were
found to possess resistant ITD clones as the driver of disease whereas in 32% of cases there
was no FLT3-ITD mutational change observed [24], indicating resistance arising from nonFLT3 dependent pathways.
Among mechanisms of resistance to TKI that arise from non-FLT3 dependent
pathways, most notable are the resistance mechanisms relating to the cell's systems which
govern the apoptotic process. While it has been noted that proteins driving survival may be
intrinsically upregulated as part of the progression of cancer, the upregulation of proteins
with pro-survival function have also been observed in response to treatment [31-33].
Specifically, the BCL-2 family of apoptotic regulators represents a rich area for therapeutic
exploration and offers a potential means for abrogating resistance to therapy.

BCL-2 Protein Family and MCL-1
Apoptosis is a highly coordinated multisequence process which governs the fate of
the cell. This can either lead to a survival state that maintains cell homeostasis or a state
leading towards the irreversible mitochondrial outer membrane permeabilization (MOMP)
in which the mitochondria release its content and engages in programmed cell death [34].
A core part of the apoptotic mosaic is the BCL-2 family of proteins which regulate the
intrinsic pathway of apoptotic activation and integrate intracellular signals in response to
stress.
8

Members of the BCL-2 family of proteins are distinguished by the structural
presence of BCL-2 Homology (BH) Domains found amongst all BCL-2 family members
[34,35]. It is through these domains that family members can interact with each other as
inhibitors, effectors, and sensitizers in the apoptosis process. The integrated sum of their
influence at the mitochondria is how ultimate cellular fate is determined.
Under healthy cellular conditions, the pro-apoptotic and pro-survival BCL-2
members balance each other out to prevent improper apoptosis induction. Core proapoptotic members include BIM, BAK, and BAX. Apoptosis is initiated through the BH3
binding of BIM to BAX/BAK at the mitochondria whereupon BAX/BAK activate and
dimerize [34, 109]. This leads to MOMP and allows for cytochrome c to be released from
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the mitochondria. The resulting effect is the activation of caspase 9 and executioner
caspases like 3 and 7 leading to cell death.
The foils to this process are the pro-survival members BCL-2, BCL-XL, and MCL1. These proteins help to maintain cellular homeostasis and prevent premature apoptosis
by interfering with BH3 interactions between pro-survival BCL-2 proteins. This is the case
with MCL-1 where binding onto BIM prevents its interaction with BAX/BAK and the
initiation of apoptosis [34]. It is only when adequate cellular stress and irreparable damage
occurs that additional molecular processes allow BIM to displace the pro-survival BCL-2
proteins and promote apoptosis.
Resistance to cell death is considered a hallmark of cancer and of significant interest
in the study of cancer, dysregulation of pro-survival BCL-2 family members occurs which
results in a failure of appropriate apoptotic activation [36]. This has led to the development
of inhibitors of pro-survival BCL-2 family members and many clinical successes over the
past years.

Targeting MCL1
Of particular interest to combating therapeutic resistance to FLT3-ITD is the prosurvival BCL-2 family member MCL-1. Across a variety of cancers MCL-1 has been found
to be highly amplified and implicated with resistance and relapse which has led to it
becoming a highly sought-after target [37-39]. In FLT3-ITD mutated AML, myeloid cell
leukemia 1 (MCL-1) protein has been found to be upregulated with its overexpression has
been implicated in the survival of acute myeloid leukemia cells, their maintenance, and
resistance to chemotherapeutics [40-43]. MCL-1 is a short-lived protein, and its expression
is tightly regulated at transcriptional, translational, and post-translational levels. MCL-1
10

functions in a similar manner as BCL-2 and has been found to have a similar sequence to
BCL-2, but due to its rapid turnover its effects are not as prolonged. At the transcriptional
level the MCL-1 gene is considered as an early responder to the cell differentiation process
[44], and it helps to stabilize the viability of the cell while avoiding cell death [45,46]
The primary means for MCL-1’s pro-survival action is through protein-protein
interactions with the pro-apoptotic proteins. Through BH3 domain binding with BIM,
MCL-1 attains structural stabilization while simultaneously preventing BIM from
engaging with BAX/BAK in a manner essential for promoting mitochondrial apoptosis
[47, 110]. Currently the primary therapeutic strategy for the inhibition of MCL-1 has been
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the development of BH3 mimetics [48] which bind to the BH3 binding groove of MCL-1
necessary for its anti-apoptotic function [49]. These small molecule inhibitors of MCL-1
mimic the peptide interaction MCL-1 has with its primary protein-interaction partner BIM.
By preventing MCL-1: BIM interactions, BIM is free to bind to BAX/BAK for pore
formation and MOMP. In turn, these BH3 mimetics can help promote sensitization to
chemotherapy.
As of spring of 2022, despite preclinical and clinical investigations of MCL-1
inhibitors there currently are no FDA approved MCL-1 inhibitors [50-53]. Currently
clinical trials are ongoing with several MCL-1 inhibitors such as AZD5991 Alone or in
Combination With Venetoclax in Relapsed or Refractory Hematologic Malignancies
(NCT03218683),

PRT1419 in Relapsed/Refractory Hematologic Malignancies

(NCT05107856), and S64315 Plus Azacitidine in Acute Myeloid Leukemia
(NCT04629443). Of relevance to our project is the selective MCL-1 inhibitor S63845. In
preclinical studies, S63845 was found to exhibit dose-dependent anti-tumor activity invitro and was found to be well tolerated by mice in the in-vivo studies [52]. Given the
relevance of MCL-1 in cancer and its role in resistance to TKI therapy, we investigated the
anti-leukemic efficacy of S63845 in combination with midostaurin for the treatment of
FLT3-ITD AML.
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Hypothesis and research aims
Hypothesis
FLT3-ITD mutated AML is dependent on Mcl-1 and is effectively eradicated with
combined inhibition of FLT3 and MCL-1

Aims
i.

Evaluation of apoptotic efficacy of concomitant FLT3 and Mcl-1 inhibition in
FLT3 mutated AML cell lines

ii.

Assess the proteins involved in midostaurin and S63845 induced apoptosis to
determine key mechanisms
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Materials and Methods
Drugs
S63845, and midostaurin were provided by the Novartis Institute for BioMedical Research
(Cambridge, MA). All other reagents, unless stated otherwise, were purchased from SigmaAldrich (St. Louis, MO). Gilteritinib and proteasome inhibitor MG-132 were purchased
from Sellekchem. Pan-caspase inhibitor zVAD was purchased from Promega.
Cell lines and primary AML cells
The AML cell lines were purchased from ATCC (Manassas, VA) or the Leibniz Institute
DSMZ, German Collection of Microorganisms and Cell Cultures (Braunschweig,
Germany).MV4;11 (FLT-ITD+/+), MOLM13 (FLT3-ITD+/-), MOLM14 (FLT3-ITD+/-),
OCI-AML3 (wild-typeFLT3), and OCI-AML2 (wild-type FLT3) cells were cultured in
RPMI supplemented with 10%fetal bovine serum (FBS), 100 IU/mL penicillin, and 100
μg/mL streptomycin (Sigma-Aldrich).Murine IL-3–dependent Ba/F3 wild-type FLT3,
Ba/F3 FLT3-ITD, Ba/F3 FLT3-ITD-D835Y,and Ba/F3 FLT3-ITD-F691L cells and human
MV4;11 FLT3-ITD-D835Y cells were a kind gift from Prof. Michael Andreeff and were
cultured as above, except for IL-3–dependent Ba/F3 wild-type FLT3 cells, which were
additionally maintained in the presence of 20 ng/uL IL-3. Venetoclax-resistant MOLM13
cells, generated as described in reference [111] were routinely maintained in complete
RPMI medium containing 1 μM of venetoclax. Cells were cultured in venetoclax-free
RPMI medium for 24 hours before experiments.
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Cell viability and synergy studies
Cells were seeded onto a 96-well plate at a density of 8 × 105/mL and treated with
DMSO(controls) or tested compounds alone or in combination for 24 hours. Cell viability
was measured using the CellTiter-Glo reagent (Promega, Madison, WI), and percent
viability was calculated by dividing relative luminescence units (RLU) of cells in treated
wells by RLU of cells in DMSO control wells. Dose-response curves and 50% growth
inhibitory concentrations (IC50) were determined using GraphPad Prism 8.3 software.
Drug synergy was additionally evaluated using the Bliss independence model as described
in. Briefly, cells were treated with nine 2-fold serial dilutions of each compound, either
individually or in all possible permutations, in a checkerboard fashion. Control cells
received DMSO. Cell viability was determined using the CellTiter-Glo viability assay after
24 hours. The expected combined effect of the 2 drugs was calculated using the equation
E(fAB)= fA + fB −(fA × fB), where fA and fB represent the percentage of growth inhibition
by the individual drugs A and B at a given dose. The difference between the observed
combined effect fAB and the expected combined effect E(fAB) of the 2 drugs is described
as Excess over Bliss. Excess over Bliss scores for each dose combination >0 represent
synergy, whereas Excess over Bliss index values <0 represent antagonism.
Western blot analysis
Cells were seeded onto 6-well plates at a density of 1 × 106 cells/mL and treated as indicated
for 6 hours. Whole cell lysates were prepared using RIPA buffer supplemented with
Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, Waltham, MA).
Protein content was measured using BSA assay. Cell lysates were separated on 4% to 20%
gradient sodium dodecyl sulfate-polyacrylamide gels (Bio-Rad, Hercules, CA), transferred
to a PVDF membrane (Bio-Rad) and incubated with following antibodies: anti-FLT3, p15

FLT3 (Y591), -STAT5, -p-STAT5 (Y694), -MAPK, -p-MAPK (T202/Y204), -AKT, -pAKT, -Gsk3,-p-Gsk3, -MCL-1, -p-MCL-1 (Ser159/Thr163), -PARP, -Cleaved caspase3, BCL-2, -BCL-XL,-NOXA, -BIM from Cell Signaling Technology (Danvers, MA) and
anti-B-actin from Sigma-Aldrich. The membranes were analyzed on an Odyssey imaging
system from LI-COR Biosciences (Lincoln, NE).
Flow cytometric measurement of apoptosis
Cells were seeded onto 48-well plates at a density of 8 × 105 cells/mL and treated with
midostaurin and S63845 alone or in combination for 16 hours. The next day, plates with
cells were centrifuged, washed once with PBS, and stained with Annexin V-APC antibody
(BD Biosciences) and 4′6-diamidino-2-phenylindole (DAPI) in Annexin V buffer for 20
minutes at room temperature in the dark. Data were collected using a Calusa flow
cytometer (Beckman) and analyzed using FlowJo software (Tree Star, Ashland, OR).
Results were displayed as percentages of Annexin V–positive cells and percentage of
specific apoptosis was calculated as follows : (100% ×
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𝐴𝑝𝑜𝑝𝑡𝑜𝑠𝑖𝑠 𝑡𝑒𝑠𝑡−𝐴𝑝𝑜𝑝𝑡𝑜𝑠𝑖𝑠 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
100−𝐴𝑝𝑜𝑝𝑡𝑜𝑠𝑖𝑠 𝑐𝑜𝑛𝑡𝑟𝑜𝑙

).

Results
Combined FLT3 and MCL-1 inhibitors synergistically kill FLT3-ITD AML cells
First, we examined the anti-leukemic efficacy of S63845 and midostaurin
combination in MV4-11 (FLT3-ITD+/+), MOLM13 (FLT3-ITD+/-), MOLM14 (FLT3ITD+/-), and MV4-11;FLT3-D835Y cells. Cell viability was measured after 24 hours of
treatment using CellTiter-Glo Assay. As shown in Figure 7A, FLT3-ITD cells were
sensitive to the tested combination and MV4-11 cells carrying FLT3-ITD+/+ displayed the
best response to treatment. Since point mutations in FLT3 tyrosine kinase domain (TKD)
confer resistance to FLT3-targeted therapy, we also tested the effect of combination in
FLT3-TKD positive AML cells. As shown in Figure 7A, MV4-11 cells carrying the D835Y
mutation were similarly sensitive to combined S63845 and midostaurin treatment.
Synergistic activity of S63845 and midostaurin was confirmed by Bliss independence
analysis (Figure 7A, bottom) where the excess over Bliss score >0 indicates synergy and
total observed synergy is represented as the Bliss synergy sum. Overall, our results confirm
sensitivity to respective treatments and synergistic activity amongst treated FLT3-ITD
positive AML cell lines.
Next, we tested efficacy of the combination in OCI-AML-2 and OCI-AML-3 cells
that express the wild-type FLT3. Cells were exposed to midostaurin, S63845 or
combination for 24 hours and analyzed using CTG assay. Although, S63845, midostaurin,
or combination decreased wild-type cell viability (Figure 7B), the overall efficacy of
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combination was much less pronounced than that seen in treated FLT3-ITD AML cells.
Subsequent Bliss independence analysis for OCI-AML-2 and OCI-AML-3 cells indicated
that inhibitory effect of combination was minutely synergistic. Indeed, when comparing
respective Bliss synergy sums between FLT3-ITD positive AML cells (Figure 7A) and
FLT3-WT AML cells (Figure 7B), the combination treatment is several times more
synergistic in the presence of the FLT3-ITD mutation. These results confirm a unique
sensitivity to combined FLT3 and MCL-1 inhibition in FLT3-ITD mutated AML that is
not observed in wild-type FLT3 AML, suggesting that inhibition of mutated FLT3 kinase
mechanistically contributes to synergy between midostaurin and S63845.
To further confirm on-target activity of midostaurin in tested combination we used
isogenic Ba/f3-WT, Ba/f3-ITD, Ba/f3-FLT3-ITD-D835Y and Ba/F3 FLT3-ITD-F691L
cell lines (Figure 8A). By studying cell lines derived from the same genetic background,
we hoped to eliminate confounding elements produced by genetic variability amongst cell
lines. In line with prior experiments, Ba/f3 cell lines with FLT3MUT status exhibited greater
sensitivity to single agent midostaurin or S63845 than treated FLT3WT Ba/f3 cells. It was
also noted that across the tested Ba/f3 cell lines the greater inhibitory effect was achieved
by the combination treatment compared to single treatment alone. Bliss Independence
Analysis confirmed that combination was highly synergistic in cells carrying FLT3
mutations compared to FLT3-WT AML cells.
Last, we replicated the 24-hour treatment experiments using an alternative FLT3
inhibitor in combination with S63845. To this end, the gilteritinib was chosen as the
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alternative FDA approved selective FLT3 inhibitor. Amongst the tested MOLM13,
MOLM14, and MV4-11 cell lines (Figure 8B), we observed similar degrees of response
to gilteritinib/S63845 as observed for midostaurin/S63845 combination (Figure 7A). Bliss
synergy sums calculated for gilteritinib and S63845 combination also indicate synergistic
effects similar to our observations with midostaurin. Together these results suggest that the
efficacy of dual FLT3 and MCL-1 inhibition is driven by the inhibition of mutated FLT3
kinase rather than an alternative mode of cytotoxicity intrinsic to midostaurin or gilteritinib.
Overall, our results provide validity for combined targeting of FLT3 and MCL-1 to
eradicate FLT3-ITD positive AML cells.
Inhibition of FLT3 and MCL-1 induces apoptosis in FLT3-ITD AML cells
Next, to elucidate the nature of the anti-leukemic activity of combined treatment
we examined the effect of dual FLT3 and MCL-1 inhibition on induction of apoptosis in
FLT3-ITD AML cells. The MOLM13, MOLM14, and MV4-11 cells were treated with
midostaurin and S63845 alone or at various dose combinations for 24 hours. After this
period, cells were processed for Annexin-V/DAPI staining and analyzed by flow cytometry
to quantify the number of apoptotic cells (Annexin-V+) occurring at each dose
combination.
As shown on representative histograms (Figure 9A), for single treatment S63845,
we observed dose-dependent apoptotic effect in the FLT3-ITD positive AML cell lines. As
conditions went from 0 nM of S63845 towards 10 nM of S63845 there was a notable
decrease of alive cells and reciprocal increase of cells undergoing apoptosis (Figure 9A).
For single treatment midostaurin, we observed dose-dependent apoptosis as the conditions
at 0 nM midostaurin increased towards 200 nM of midostaurin. For the
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combination of S63845 and midostaurin, we observed a significant increase in apoptosis
when compared against the apoptotic effect achieved at the same dose level for either of
the single treatment S63845 or midostaurin (Figure 9A). Next, data from flow cytometry
was normalized to calculate the amount of specific apoptosis using the formula
(100% ×

𝐴𝑝𝑜𝑝𝑡𝑜𝑠𝑖𝑠 𝑡𝑒𝑠𝑡−𝐴𝑝𝑜𝑝𝑡𝑜𝑠𝑖𝑠 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
100−𝐴𝑝𝑜𝑝𝑡𝑜𝑠𝑖𝑠 𝑐𝑜𝑛𝑡𝑟𝑜𝑙

). As shown in Figure 9B, combined treatment

induced profound apoptosis in tested AML cells. Bliss Independence analysis confirmed
that the pro-apoptotic effect of midostaurin and S63845 combination was synergistic
(Figure 9B, bottom panel). Overall, these data support our prior observations from
CellTiter-Glo analysis (Figure 1) and indicate that observed decrease in cell viability upon
combined treatment results from effective activation of apoptotic programs in FLT3-ITD
AML cells.
Next, we further validated the strategy of combination FLT3 and MCL-1 inhibition
by examining apoptosis induced by S63845 and giilteritinib combination. For both S63845
and gilteritinib we observed the trend of dose-dependent apoptotic outcome as respective
single agent doses for each drug increases (Figure 10A). Likewise, after processing data
and analyzing for synergy by Bliss Independence analysis, we observed a similar trend of
synergistic pro-apoptotic effect (Figure 10B) as we did for midostaurin/S63845
combination (Figure 9B). Most notable, when comparing the Bliss synergy sums between
combination of S63845 with midostaurin (Figure 9B) or with giltertitinib (Figure 10B)
amongst the tested AML cells, MV4-11 was more sensitive than MOLM13 or MOLM14
cells. This heightened sensitivity may indicate that FLT3-ITD+/+ AML responds more
favorably to the combined MCL-1 and FLT3 inhibition as a result of stronger dependency
on

FLT3-ITD+/+

for

survival

than
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FLT3-ITD+/-

cells.

While
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these results support the role of MCL-1 in TKI resistance in FLT3-ITD AML, it also
demonstrates that the combination of FLT3 and MCl-1 inhibition produces improved
results regardless of the FLT3-ITD allele number. Overall, our results demonstrate that the
combined targeting of MCL-1 and mutated FLT3 produces superior inhibitory effect in
both FLT3-ITD+/+ and FLT3-ITD+/- in comparison to single agent treatment.
To support our CellTiter-Glo and Annexin-V/DAPI data, next we examined
cleaved PARP and cleaved caspase-3 which serve as molecular markers of apoptosis. The
MOLM13, MOLM14, and MV4-11 cells were incubated for 6 hours with 100 nM
midostaurin,10 nM S63845, and combination. Cells were then processed for Western Blot
analysis. In Figure 11A, both single agent midostaurin and S63845 produce moderate
PARP and caspase-3 cleavage in the treated FLT3-ITD positive cell lines. Importantly,
drug combination led to significant increase in cleavage for both PARP and caspase-3
compared to a single agent treatment.
Similar effect was demonstrated for S63845 and gilteritinib in the MV4-11 cells.
Greater PARP and caspase-3 cleavage, corresponding to profound apoptosis, was achieved
by combined treatment over single treatment conditions (Figure 11B). These results
support the observation that S63845 and midostaurin act synergistically to promote
apoptosis in FLT3-ITD positive AML.
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Midostaurin and S63845 combination integrates separate modes of MCL-1
suppression
The results from the previous section served to validate the strategy of using
combined MCL-1 and FLT3 inhibition to improve outcomes in FLT3-ITD positive AML.
The vastly improved induction of apoptosis with dual therapies raised the important
question of “What is the molecular basis underlying observed synergy?”. To answer this,
26

we sought to investigate deeper into the signaling pathways triggered upon dual FLT3 and
MCL-1 inhibition.
First, we examined the impact of combined FLT3 and MCL-1 inhibition on MCL1 protein levels in FLT3-ITD AML. This led us to test the effect of midostaurin on MCL1 levels in both FLT3-ITD positive AML and FLT3-WT AML cell lines. Cells were
incubated with either DMSO or 100 nM midostaurin for 6 hours then analyzed by Western
Blot to examine MCL-1 expression. In response to midostaurin the level of MCL-1
significantly decreased in FLT3-ITD positive cells (Figure 12). In contrast, in the FLT3WT cells, midostaurin did not reduce MCL-1 expression (Figure 12). These results
indicate that MCL-1 expression may be regulated by FLT3-ITD. Recent studies have
shown that FLT3-ITD dependent STAT5 activation can lead to excessive translation of
MCL-1 [66] while MAPK activation, through phosphorylation, prevents proteasomal

27

degradation of MCL-1, leading to its increase. Thus, next we examined the effect of
combination on the FLT3-ITD downstream effectors.
MOLM14 and MV4-11 cells were incubated with DMSO, midostaurin, S63845, or
combination for 6 hours and analyzed through Western blot. As shown in Figure 13A,
midostaurin treatment leads to downregulation of the phosphorylated form of the FLT3ITD receptor. A subsequent decrease in phosphorylation was also seen for downstream
FLT3 effectors: MAPK, STAT5, and AKT (Figure 13A). S63845 alone did not change
levels of P-FLT3 nor in P-MAPK, P-STAT5, and P-AKT compared to DMSO control
(Figure 13A). Lastly, in combination treatment, we observed a replication of results
observed for midostaurin only without added impact by S63845 (Figure 13A). Similar
effect was observed for gilteritinib and S63845 in MV4-11 cells (Figure 13B). These
results support the expected inhibitory effect of midostaurin on the FLT3 pathway and
provide evidence that S63845 alone does not directly impact phosphorylation of key
components of FLT3 signaling.
After exploring the FLT3 pathway, we next looked at the effect of combined
treatment on expression of MCL-1 and BIM in MV4-11 and MOLM14 cells. BIM is
important for promoting apoptosis since it activates oligomerization of apoptotic effectors
BAK/BAX to promote mitochondrial outer membrane permeabilization (MOMP) [67].
Under physiological conditions, BIM is sequestered by MCL-1 to prevent apoptosis [68].
As shown in Figure 13C, midostaurin alone decreased MCL-1 protein levels (Figure 13C)
with residual MCL-1 remaining. This incomplete suppression of MCL-1 by midostaurin
alone was concordant with our previous observations (Figure 12). S63845 alone elevated
MCL-1 protein level (Figure 13C). This effect was within expectations as S63845 is
28
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reported to inhibit MCL-1 while stabilizing the protein [52]. Lastly combined treatment
reduced MCL-1 protein level like that observed for midostaurin alone (Figure 13C). In
examining BIM there was a visible shift in protein electrophoretic mobility in response to
midostaurin alone or in combination with S63845 treatment. The upward shift likely
represents the phosphorylated form of BIM. Midostaurin increased downward shift in BIM
mobility which corresponds to decreased BIM phosphorylation (Figure 13C). Similarly,
gilteritinib alone or in combination with S63845 reduced MCL-1 level and changed BIM
electrophoretic mobility (Figure 13D). As BIM in the phosphorylated state becomes
inactivated, it is likely that the inhibition of FLT3 promotes BIM activation by preventing
its phosphorylation and sequestration by MCL-1. Together, we propose that inhibition of
FLT3 signaling leading to the downregulation of MCL-1 and activation of proapoptotic
BIM, supported by blocking residual activity of MCL-1 by S63845 and release of BIM
otherwise sequestered by MCL-1, may underlie the synergy of the tested combination
observed in FLT3-ITD positive AML cells.

Midostaurin-mediated activation of Gsk3 promotes enhanced proteasomal
degradation of MCL-1
Our work so far has highlighted the relevance of MCL-1 suppression and its impact
on AML cell viability in response to combined FLT3 and MCL-1 inhibition. While much
background work has been established to elucidate the mechanism of MCL-1 inhibition by
S63845 [52], the means in which FLT3 inhibition suppresses MCL-1 remains obfuscated.
Left open is the question of “How does inhibition of FLT3-ITD contribute to the
downregulation of MCL-1?”. Therefore, we next examined the kinetics of molecular
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events triggered in response to FLT3 inhibition. To that extent MV4-11, MOLM13, and
MOLM14 cells were treated at various time points with 100 nM midostaurin and analyzed
by Western Blot in order to assemble an hour-by-hour snapshot of molecular events.
Upon the first hour of treatment with midostaurin, we observed an immediate down
regulation of phosphorylation in FLT3 and its downstream effectors AKT and MAPK, as
well as Gsk3 (Figures 14A and 15A). Parallel to the deactivation of AKT and MAPK, a
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gradual loss of MCL-1 was accompanied by decrease in pro-apoptotic NOXA and shift in
BIM electrophoretic mobility (Figure 14B and 15B).
A closer look at the phosphorylation status of MCL-1 showed that MCL-1 was
phosphorylated at Ser159/Thr163 within the first 2 hours of midostaurin treatment, where
Ser159 and Thr163 are phosphorylated respectively through Gsk3 and MAPK [56,57]. At
the same time the level of NOXA remained unaffected. A decline in MCL-1
Ser159/Thr163 phosphorylation and NOXA expression was visible after 4 hours of
exposure to midostaurin and accompanied by the decrease in total level of MCL-1 (Figure
14A). In context of the immediate down regulation of phosphorylation of Gsk3 observed
at 1 hour of treatment, the sequence of events suggests that activation of Gsk3 preceded
MCL-1 downregulation and imply that midostaurin treatment may induce proteasomal
degradation of MCL-1. In parallel, at early time points of midostaurin treatment, there is
enough endogenous NOXA to sequester MCL-1 and trigger its degradation visible at later
time points of treatment (4-6 hours). Importantly, despite the decrease in MCL-1 level,
BCL-XL and BCL-2 protein expression remained unaffected upon midostaurin exposure
(Figures 14B and 15B). These results indicate that midostaurin alone effectively suppress
the anti-apoptotic response by affecting MCL-1 level without activating compensatory
upregulation of BCL-XL or BCL-2.
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To provide support that midostaurin-induced MCL-1 protein downregulation was
a result of increased proteasomal degradation, we treated FLT3-positive AML cells with
100 nM midostaurin for 6 hours with or without pretreatment with the proteasome inhibitor
MG-132. As MCL-1 phosphorylation mediates protein stability [56,57], we first looked at
relationship between proteasomal degradation and total MCL-1 level. Western blot
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analysis indicated that MG-132 alone increased MCL-1 levels in a dose-dependent manner,
consistent with blocking of proteasomal turnover of MCL-1 (Figure 15A). While
midostaurin alone, as expected, significantly reduced MCL-1 level, pretreatment with MG132 profoundly inhibited this downregulation beyond baseline conditions. This effect was
especially visible when higher dose (1 uM) of MG-132 was used in combination with
midostaurin. A similar pattern of response was also observed for NOXA protein.
midostaurin alone reduce NOXA levels, while MG-132 prevented its downregulation
(Figure 16A) suggesting that NOXA as a binding partner of MCL-1 is not only involved
in its proteasomal degradation [58-60] but is also co-degraded with MCL-1 [60]. Together,
these observations implicate the involvement of the proteasome degradation system as the
mechanism for observed downregulation of MCL-1 in FLT3-ITD expressing cells upon
midostaurin treatment, which may contribute the overall anti-leukemic efficacy of
midostaurin and S63845 combination.
Since MG-132 did not completely abolish MCL-1 degradation in response to
midostaurin treatment, next we examined the potential contribution of apoptotic caspase
cleavage in driving the downregulation of MCL-1. FLT3-ITD positive AML cells were
treated with 100nM of midostaurin for 6 hours with or without pretreatment with the pancaspase inhibitor Z-VAD-FMK and analyzed by Western Blot. As expected, midostaurin
alone reduced the level of MCL-1 (Figure 15B). Pretreatment with Z-VAD-FMK led to
accumulation of MCL-1 in both untreated and midostaurin treated-cells, however this was
not to the extent observed upon proteasome inhibition (Figure 15B). In the case of NOXA,
in comparison to midostaurin alone, Z-VAD-FMK pretreatment also prevented its
cleavage, although the observed effect was not as prominent as in the case of MCL-1,
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most likely due to the low levels of endogenous NOXA. These results indicate that while
MCL-1 downregulation upon FLT3 inhibition is primarily executed through activation of
ubiquitin-proteasome pathway, this effect is also complemented by parallel caspasemediated degradation of MCL-1.
Dual FLT3 and MCL-1 inhibition is synergistic in venetoclax resistant FLT3-ITD
AML cells
BCL-2 is an anti-apoptotic protein whose dysregulation serves to promote
apoptosis evasion in cancer [62]. While effective BCL-2 inhibition is achieved with the
BH3-mimetic venetoclax, treatment failure has been often found to correlate with the
presence of mutated FLT3-ITD [63]. In addition, the effective response to venetoclax
monotherapy was hindered by the switch in cell dependence from BCL-2 to other BCL-2
family members like MCL-1 or BCL-XL for the survival manifested by upregulation of
these proteins [64,65]. Therefore, we next tested whether combined targeting of FLT3-ITD
and MCL-1 may be an alternative option for elimination of AML cells with acquired
resistance to venetoclax. Here, we used MOLM13 cells conditioned to develop resistance
to venetoclax by prolonged exposure to increasing doses of the drug (up to 1 M)[100].
First, we examined the effect of S63845 and midostaurin on MCL-1 and BCL-2
expression. As shown in Figure 17, venetoclax resistant MOLM13 cells had a much
greater baseline expression of MCL-1 compared to the levels of MCL-1 expressed at
baseline for parental MOLM13 cells. This was in agreement with previous observations
indicating that venetoclax resistant cells expressed elevated MCL-1 to compensate for nonfunctional Bcl-2 protein [61]. Despite upregulation of MCL-1, midostaurin still downregulated MCL-1 in venetoclax resistant cells, just as it was observed for parental
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MOLM13 cells (Figure 17). Similarly, S63845 increased stability of MCL-1 in both
parental and venetoclax resistant MOLM13 cells (Figure 17). Combined treatment in
parental MOLM13 cells reduced MCL-1 expression to a similar extent as observed for
midostaurin alone (Figure 17). In venetoclax resistant MOLM13 cells the combination
produced a greater reduction of MCL-1 than midostaurin alone (Figure 17) suggesting
more profound efficacy of combined treatment. In looking at BCL-2 levels for both cell
lines, there was no observed change induced by respective therapies in single agent or
combination treatment (Figure 17).
Next, we examined the inhibitory effect of S63845 and midostaurin at various dose
combinations in parental and venetoclax resistant MOLM13 cell lines. After 24-hour drug
exposure, CTG viability assay revealed that in the venetoclax resistant MOLM13 cells
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there was a profound therapeutic response to single agent S63845 treatment compared to
the response observed in parental MOLM13 cells (Figure 18). These results confirm the
dependency of venetoclax resistant cells on MCL-1 for survival. Importantly, the
subsequent Bliss independent analysis indicated greater synergistic effect occurring for the
drug combination in venetoclax resistant Molm13 cells.
Last, we examined the induction of specific apoptosis in response to the drug
combinations using Annexin V-FITC/DAPI staining and flow cytometry. Compared to
parental MOLM13 cells, venetoclax resistant cells were more sensitive to midostaurin or
S63845 single agent treatment (Figure 19A). Similarly, combined S63845 and midostaurin
treatment lead to more profound apoptosis in venetoclax resistant MOLM13 cells
compared to the parental counterpart (Figure 19A). Subsequent Western Blot
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analysis of apoptotic markers e.g., cleaved caspase-3 and PARP supported these
observations. As shown in Figure 19B, venetoclax resistant MOLM13 cells exhibited a
superior caspase-3 and PARP fragmentation in response to S63845 and combination
treatment conditions than parental MOLM13 cells. Together, these results indicate that
dual targeting of MCL-1 and mutated FLT3 is highly effective in AML cells resistant to
venetoclax.

Discussion
Dual FLT3 and MCL-1 inhibition synergistically achieves cell death in FLT3-ITD
AML
Encouraging responses have been achieved with FLT3 TKI-based regimens in both
the frontline and relapsed/refractory settings to treat FLT3-ITD mutated AML. Despite this
there are still many patients, usually older, who either fail to respond to FLT3 inhibitor
therapy or achieve a limited period of remission prior to succumbing to relapse [24,26].
This observation underlies the challenges faced with the eradication of FLT3-ITD AML
and the potential for resistance arising from both mechanisms within the FLT3 pathway
and mechanisms outside of the FLT3 pathway [24]. Means for improving FLT3-ITD AML
treatment response has been explored and evidence has been found to supports use of BCL2 family inhibition in combination with FLT3 inhibitors [97-99]. In seeking to improve
outcomes in this AML subset, we demonstrate the synergistic efficacy of combination of
midostaurin and MCL-1 inhibitor S63845 in eradicating FLT3-ITD mutated AML cells in
pre-clinical settings.
One of the mechanisms of reduced response of AML to TKI is through the presence
of mixed alleles of both FLT3-ITD and FLT3-WT [26]. In our studies we observed the
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synergistic effect of combination for both FLT3-ITD(+/+) and FLT3-ITD(+/-) cells. In
FLT3-ITD(+/+) cells the combination proved to be the most lethal while in FLT3-ITD(+/-)
cells the effect was observed to be effective but reduced. This may be partly due to the
ability of FLT3-ITD receptors to dimerize with both other FLT3-ITD receptors as well as
with the wild-type receptor form [27]. It is also possible that mixed allele phenotype may
still have a response to FLT3 ligand for survival signals despite the presence of effective
TKI treatment [26-29]. This form of resistance seems likely to be intrinsic at the start of
therapy rather than one arising in response to treatment [24]. Allelic ratio may help to
explain differences in response to initial treatment, but not the development of
resistance. Relating this to our results, we observed regardless of mutation status that AML
cells with the wild-type FLT3 receptor were still less sensitive than FLT3-ITD mutants to
combination therapy.
The development of additional mutations in the FLT3 receptor is another key driver
for lack of response and resistance development [24,26]. AML exists as a genetically
heterogeneous population of cells, and it is possible for subpopulations of cells to further
mutate independent of treatment administration. Common FLT3 mutations occur around
the Tyrosine Kinase Domain (TKD) of the FLT3 receptor and were studied in our project.
We examined the effect of our combination on FLT3-TKD mutated F691L and D835Y
cells and verified that dual targeting of FLT3 and MCL-1 acts synergistically in FLT3TKD mutated AML to induce cell lethality. While this type of mutation is a rare means of
therapy resistance [30], we report that the mutation does not abrogate the lethal effect of
combined midostaurin and S63845 treatment. Overall, our results indicate strong
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synergistic response of the midostaurin and S63845 combination in FLT3-ITD mutated
AML cells at dose ranges that otherwise have been ineffective as monotherapy.

Combination promotes BIM accumulation and apoptotic activity
Given the sensitivity towards MCL-1 suppression by combination midostaurin and
MCL-1 inhibitor S63845, the FLT3-ITD AML cells are reliant on MCL-1 for survival. In
this context, we propose that the key molecular mechanism of the combination lethality
involves the promotion of pro-apoptotic BIM activation. BIM is key for promoting
BAK/BAX mediated apoptosis and MCL-1 serves as a potent antagonist of BIM apoptosis
function. During BIM: MCL-1 complex formation, MCL-1 prevents BIM binding to
apoptotic inducers to promote cell death [90]. Thus, therapeutic suppression of MCL-1
protein should serve as a means of preventing antagonistic binding with BIM. This in turn
would promote the activated state of BIM and influence towards apoptotic cell death.
In our Western Blot analysis, the greatest induction of molecular markers of
apoptosis was observed during treatment with combination midostaurin and S63845. For
midostaurin only conditions, the downregulation of MCL-1 protein was observed with
residual MCL-1 remaining. For combination conditions, the greater lethal effect observed
was likely produced through S63845 inhibition of remaining MCL-1. The combined attack
to reduce MCL-1 and inhibit residual protein in aggregate supports in part the combination
lethality occurring as a result of preventing antagonistic MCL-1 interactions with BIM.
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For our Western Blot analysis of BIM under midostaurin treatment conditions, we
observed the dephosphorylation of BIM as indicated by its phospho-mobility shift along
with the accumulation/stabilization of BIM protein level. This increase in BIM stabilization
may indicate a means in which midostaurin supports BIM activation. Past research
indicates that multiple phosphorylation sites exist on BIM which can be posttranslationally modified through the AKT and MAPK pathways to influence its
proteasomal degradation [91-93,112]. As midostaurin suppresses kinase activity within the
AKT and MAPK pathways, midostaurin-mediated prevention of phosphorylation of BIM
helps to explain stabilization of the BIM protein observed. BIM dephosphorylation and
increased observed protein accumulation lends supports to promotion of pro-apoptotic
BIM activation.
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In addition to stabilizing BIM, an alternative implication of BIM dephosphorylation
supports the promotion of BIM pro-apoptotic function through decreased affinity towards
MCL-1 thus decreasing susceptibility to inhibition by MCL-1. In a study examining the
mechanism of action of BCL-XL inhibitor ABT-737 in multiple myeloma, it was found
that BIM phosphorylation promotes association with MCL-1 and dephosphorylation of
BIM by MEK inhibition was able to shift binding towards other anti-apoptotic proteins
such as BCL-2 and BCL-XL [94,95,112]. Furthermore, a study with RPCI-WM1 cells
examining the effect of disrupting or fortifying various BIM phosphorylation sites
observed differences in protein-protein associations through the ratio of BIM
immunoprecipitation with MCL-1, BCL-XL, or BCL-2 [96]. In context to our study, the
combined suppression of MCL-1 by midostaurin and S63845 treatment may be
accompanied by BIM having lowered sensitivity to inhibition by MCL-1. As Western Blot
analysis indicates only the upregulation of MCL-1 rather than BCL-2 or BCL-XL, the
levels of BIM maybe sufficient to bind alternative anti-apoptotic proteins from preventing
BAK/BAK dimerization and apoptosis.

Dephosphorylation of MCL-1 promotes degradation
The overall mechanism for the combination replies on the effective induction of
apoptosis through supporting activators of apoptosis such as BIM. Another important
component is repression of MCL-1. In FLT3-ITD AML, the up regulation of MCL-1 has
both transcriptional and post-translational components. Through the ITD mutation, the
FLT3 receptor gains the ability to activate STAT5 to promote the transcription of MCL-1
[33]. At the post-translational level, MCL-1 is a labile protein with rapid turnover with
phosphorylation sites on MCL-1 act in concert to promote protein stability or degradation
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[44]. The PEST (Proline, Glutamic acid, Serine, and Threonine) sites of MCL-1 modulate
phosphorylation for ubiquitin ligase interaction for proteasomal degradation [78-81].
Our results provide evidence that midostaurin induces significant reduction of
MCL-1, which correlates with the reduction of p-S159/T163 MCL-1. Phosphorylation
status of glycogen synthetase kinase 3 (Gsk3) and MAPK has been previously shown to
contribute to the respective degradation or stabilization of MCL-1 [56,57]. Both
phosphorylated AKT and MAPK have been shown to inhibit to Gsk3 by phosphorylation.
Correspondingly, the inactivation of both AKT and MAPK may be driving Gsk3 activation
[57, 114, 115]. Gsk3 when active, serves as a crucial kinase responsible for
phosphorylation of MCL-1 at Ser159 when combined with priming phosphorylation by
MAPK at T163 [116]. This results in targeting of MCL-1 for ubiquitination and subsequent
proteasomal degradation. On the other hand, MAPK-mediated phosphorylation of MCL-1
at Thr163 (probably in conjunction with phosphorylation of Thr92) and without Gsk3
mediated phosphorylation results in increased stability of MCL-1 [69, 113]. We validate
that proteasome processes are the prime means of MCL-1 degradation. The reduction of
both p-MCL-1 and total MCL-1 was rescued by inhibition of proteasome activity which
indicate that the reduction of MCL-1 expression observed can be explained through posttranslational modification rather than suppression of transcriptional elements such as
STAT5.
We see that inhibition of downstream FLT-3 pathway plays an important role
promoting the destabilization and proteasomal degradation of MCL-1. This in turn
significantly reduces the amount of available MCL-1 able to bind BIM and prevent
BAK/BAX MOMP. Correspondingly, we observed that use of FLT3 inhibition alone does
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not completely eradicate MCL-1 expression. It is possible that there is a pool of MCL-1
that due to an unclear rate limiting factor is not able to be targeted for degradation or that
despite targeting does not degrade. This lends to a reason why the additional mode of MCL1 inhibition by S63845 facilitates synergistic response in FLT3-ITD cells. Postmidostaurin treatment, residual MCL-1 still functions as a potent antagonist of apoptosis
and nullification of its function is necessary for the effective induction of apoptosis.
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MCL-1 and NOXA degradation correlate with FLT3 inhibition
As the primary antagonist of MCL-1, we were also interested in the interaction of
MCL-1 with proapoptotic NOXA protein. Apart from PEST phosphorylation
modifications by Gsk3 and MAPK, MCL-1 proteasomal degradation can also be
influenced by the proapoptotic BH3-only protein NOXA [70]. In a complex with MCL-1,
NOXA can promote its degradation through facilitation of recruitment of the ubiquitinase
MULE to MCL-1 [82] or undergo co-degradation involving the MARCH5 ubiquinatase
[83]. NOXA is noted to help promote apoptosis indirectly by occupying the MCL-1 BH3
domain and preventing inhibitor interactions with the BH3 site of pro-apoptotic proteins.
In our study, midostaurin led to the concomitant decrease of both NOXA and MCL-1. This
effect was reversed with use of proteasome inhibitor, indicating that change in NOXA level
occurred at the post-translational level. Given that both NOXA and MCL-1 both decrease
after midostaurin treatment it is plausible to speculate two scenarios of NOXA degradation.
In the first scenario, midostaurin treatment leads to the NOXA-independent
proteasomal degradation of total MCL-1, which in turn allows free NOXA to be vulnerable
to proteasomal degradation by preventing formation of NOXA: MCL-1 complex. NOXA
has been reported to contain endogenous degradation signals independent of ubiquitination
within the NOXA structure towards C-terminal [84]. When in complex with MCL-1,
NOXA is protected from degradation [85]. In this scenario, NOXA expression is decreased
as a consequence of decreased MCL-1 to bind and help stabilize NOXA.
In the second scenario midostaurin treatment leads to NOXA-dependent
proteasomal co-degradation with MCL-1 mediated by MARCH5. Depletion of NOXA and
MCL-1 occurs by MARCH5-mediated ubiquitination, where NOXA serves to facilitate
necessary localization to the mitochondria and act as structural scaffolding for the
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MARCH5-mediated ubiquitination of MCL-1 [86]. While the complete mechanism
governing NOXA:MCL-1 co-degradation by MARCH5 is still under investigation, the
current work stresses the importance of the NOXA:MCL-1 interaction rather than simple
degradation governed by phosphorylation status of MCL-1 [87].
Overall, each scenario supports the notion that apoptotic induction by combination
midostaurin and S63845 is not solely reliant on down-regulation and inactivation of MCL1, but also on the modulation of interactions of MCL-1 with other members of BCL-2
family proteins. Given that binding of BIM can protect MCL-1 from alternative BH3
binding with antagonist such as the E3 ubiquitin ligase MULE or NOXA [88-90], further
study is required to elucidate whether decreased affinity BIM with MCL-1 is directly
responsible for an increase in its degradation with or without NOXA.

Dual inhibition of MCL-1 and FLT3 overcome venetoclax resistance
In the broader landscape of cancer therapy, resistance of AML to the FDA approved
drug venetoclax represents an alternative means of diminished response. Since antiapoptotic functions of BCL-2 often underlie resistance to standard chemotherapy, this
protein has become an attractive target to help sensitize AML to therapy [71,72].
Alternatively, resistance to BCL-2 inhibition can be adaptive and while the mechanism
varies across cancers, a key means has been the upregulation of the antiapoptotic protein
MCL-1. Prior work in our lab has noted the upregulation of MCL-1 as a means of AML
compensation against single agent venetoclax treatment [100] and has been noted across a
variety of types of cancers as a means of response [74-77]. In addition, it has been observed
that FLT3-ITD mutated models that the combination of activated pathways helps to
mediate resistance towards venetoclax [101]. It has also been seen in patient samples,
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FLT3-ITD mutations serve as a means of resistance at baseline as well as newly developed
at time of relapse [73,102].
Our experiments found support of MCL-1 upregulation in the venetoclax resistant
MOLM13 cell model as a primary means of compensation against apoptosis induction,
with Western blot analysis confirming high elevation of MCL-1 without elevation in BCL2. Our results show high sensitivity towards the combination of midostaurin and S63845
in MOLM13 venetoclax resistant cells. The increased sensitivity to treatment upon
combined modalities downregulating MCL-1 highlights the increased dependency on
MCL-1 for survival. Overall, our results support the use of this combination to overcome
barriers posed by FLT3-ITD mutation status and shift towards MCL-1 dependence for
survival.
We also note reduction of the impact of midostaurin on MOLM13 venetoclax
resistant cells which suggests that acquisition of venetoclax resistance may also decrease
the efficacy of FLT3-ITD inhibitors. This is relevant to note as there is ongoing pre-clinical
research examining the combination of BCL-2 and FLT3 inhibition in AML [103,104] as
well as clinical research examining the combination of venetoclax and FLT3 inhibitor
quizartinib in relapse/refectory AML (NCT03735875).
As the development of resistance to venetoclax therapy is plausible the addition of
selective inhibitors of MCL-1 maybe be necessary as a second line of treatment upon
relapse which may help to maintain efficacy of FLT3-ITD inhibition. Furthermore, while
not explored in this thesis the continued examination of BIM, MCL-1, and NOXA in
context of venetoclax resistance may represent an additional area of study as a means of
maintaining response in AML with FLT3-ITD mutations.
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Conclusion
In sum, our collective preclinical data supports the combination of the MCL-1 inhibitor
S63845 with the FLT3 inhibitor midostaurin in FLT3-ITD mutated Acute Myeloid
Leukemia. The combination synergistically induces lethal effect in FLT3-ITD mutated
AML cells through targeting the cellular defenses to resist apoptosis. Midostaurin promotes
the proteasomal degradation of MCL-1 while encouraging the accumulation of proapoptotic protein BIM. This serves to increase dependence of AML cells on MCL-1 for
survival, thus sensitizing cells to S63845 treatment. Incidentally we also noticed the
concomitant decrease of the pro-apoptotic protein NOXA coinciding with MCL-1
degradation. While speculative, co-degradation of NOXA with MCL-1 highlights the
potential significance of sensitizers of apoptosis alongside apoptotic activators such as BIM
in treating FLT3-ITD mutated AML. Lastly, our study demonstrates the therapeutic benefit
of the combination of S63845 and midostaurin in venetoclax resistant FLT3-ITD AML
cells. Indicative of increased dependence on MCL-1 for survival, we noted a significant
increase in sensitivity to the combination in venetoclax resistant FLT3-ITD AML cells.
This supports the use of the combination of S63845 and midostaurin as a second line
treatment in the event of treatment failure or relapse post-venetoclax therapy in FLT3-ITD
AML. Overall, the combination of S63845 and midostaurin represents a new therapeutic
avenue for addressing therapy resistance and relapse for the treatment of FLT3-ITD
mutated AML.
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Future Directions
Beyond testing the efficacy of the combination therapy of S63845 and midostaurin
we need to further study the rational mechanism of action involving the coordination of
apoptotic regulation between MCL-1, NOXA, and BIM. While our study validates the
strategy of inducing apoptosis through the effective suppression of MCL-1, the full role of
NOXA and BIM remains unexplored.
One question to ask is whether the presence of available NOXA is essential for the
effective midostaurin-mediated degradation of MCL-1? For this inquiry, a study of
midostaurin induced proteasomal degradation of MCL-1 in context of NOXA silencing
would be warranted. While speculative, NOXA may prove to be a rate limiting factor for
the degradation of MCL-1 in FLT3-ITD AML which would explain the synergistic impact
observed when S63845 is combined with midostaurin.
Furthermore, another area of examination is support for the relevance of BIM for
promoting apoptosis in our combination mechanism. While the data presented in this paper
supports the accumulation of BIM as a key event for promoting apoptosis, further support
is required to support the claim of necessity of BIM for promoting apoptosis after treatment
combination. To this end, we are studying the effect of midostaurin in BIM KO in FLT3ITD AML cells to validate the essential role BIM has for the induction of apoptosis.
Furthermore, we are also examining effect of combination treatment on BAK and
BAX KO FLT3-ITD AML cells. As the BAK/BAX serves as the primary channel for
mitochondrial MOMP and BIM the activator, our studies examining the efficacy of the
combination in the respective cells with BIM knock-out will help to strengthen the
importance of BIM.
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